Search

Displaying results 4111 - 4120 of 8172 in total
  1. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    Alglucosidase alfa degrades glycogen by catalyzing the hydrolysis of a-1,4- and a-1,6- glycosidic linkages of lysosomal glycogen.

    Categories: Glycogen Storage Disease Type II, Hydrolytic Lysosomal Glycogen-specific Enzyme
  2. Drug

    Almonertinib

    go.drugbank.com/drugs/DB16640
    ApprovedInvestigational

    Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to t...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  3. Drug

    Garden snail mucin

    go.drugbank.com/drugs/DB14244
    Investigational

    Garden snail mucin is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  4. Drug

    Marine collagen, soluble

    go.drugbank.com/drugs/DB14246
    Investigational

    Marine collagen, soluble is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Canertinib

    go.drugbank.com/drugs/DB05424
    Investigational

    Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo.

  6. Drug

    Bufexamac

    go.drugbank.com/drugs/DB13346
    ApprovedWithdrawn

    The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822].

    Synonyms: 2-(p-Butoxyphenyl)-acetohydroxamic acid, p-Butoxyphenylacetohydroxamic acid
  7. Drug

    Etretinate

    go.drugbank.com/drugs/DB00926
    ApprovedWithdrawn

    Etretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas.

  8. Drug

    Methylcellulose

    go.drugbank.com/drugs/DB11228
    ApprovedInvestigational

    The Degree of Substitution (DS) of a given form of methyl cellulose is defined as the average number of substituted hydroxyl groups per glucose with a theoretical maximum of 3, however more typical values

  9. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). Hypophosphatasia is almost always fatal when severe skele...

  10. Drug

    Avutometinib

    go.drugbank.com/drugs/DB15254
    ApprovedInvestigational

    Avutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, diff...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates